Treatment with Injectable Platelet-Rich Fibrin in a Rat Model of Melasma
October 2023
in “
European journal of dermatology/EJD. European journal of dermatology
”
Studysummary In this study, I-PRF, a blood-derived biomaterial without anticoagulants, was found to inhibit melanin production and reduce oxidative stress damage in a rat model of melasma, suggesting it as a safe and cost-effective treatment option.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study evaluated the efficacy of injectable platelet-rich fibrin (I-PRF) in treating melasma using a rat model. Sprague Dawley rats with melasma were divided into experimental and control groups, with the experimental group receiving weekly intradermal injections of I-PRF and the control group receiving saline. After four weeks, the results showed that I-PRF inhibited melanin production in the epidermis and reduced oxidative stress damage in the cortex, leading to an improvement in melasma. The study concluded that I-PRF is a safe and cost-effective treatment for melasma.
